- Home
- BKE vs MIRM Comparison
BKE vs MIRM Comparison
Compare BKE & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKE
- MIRM
- Stock Information
- Founded
- BKE 1948
- MIRM 2018
- Country
- BKE United States
- MIRM United States
- Employees
- BKE N/A
- MIRM N/A
- Industry
- BKE Clothing/Shoe/Accessory Stores
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- BKE Consumer Discretionary
- MIRM Health Care
- Exchange
- BKE Nasdaq
- MIRM Nasdaq
- Market Cap
- BKE 2.4B
- MIRM 2.5B
- IPO Year
- BKE 1992
- MIRM 2019
- Fundamental
- Price
- BKE $41.17
- MIRM $52.45
- Analyst Decision
- BKE Hold
- MIRM Strong Buy
- Analyst Count
- BKE 1
- MIRM 11
- Target Price
- BKE $46.00
- MIRM $57.00
- AVG Volume (30 Days)
- BKE 436.1K
- MIRM 504.4K
- Earning Date
- BKE 03-14-2025
- MIRM 02-26-2025
- Dividend Yield
- BKE 9.48%
- MIRM N/A
- EPS Growth
- BKE N/A
- MIRM N/A
- EPS
- BKE 3.94
- MIRM N/A
- Revenue
- BKE $1,220,873,000.00
- MIRM $307,028,000.00
- Revenue This Year
- BKE N/A
- MIRM $83.04
- Revenue Next Year
- BKE $2.70
- MIRM $27.22
- P/E Ratio
- BKE $10.45
- MIRM N/A
- Revenue Growth
- BKE N/A
- MIRM 112.14
- 52 Week Low
- BKE $34.87
- MIRM $23.14
- 52 Week High
- BKE $54.25
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- BKE 24.16
- MIRM 64.07
- Support Level
- BKE $42.04
- MIRM $51.02
- Resistance Level
- BKE $43.77
- MIRM $53.76
- Average True Range (ATR)
- BKE 1.07
- MIRM 2.04
- MACD
- BKE -0.20
- MIRM 0.03
- Stochastic Oscillator
- BKE 2.24
- MIRM 73.31
About BKE Buckle Inc. (The)
Buckle Inc is a retailer of casual apparel, footwear, and accessories. The company retails medium to better-priced casual apparel, footwear, and accessories for fashion-conscious young men and women. It retails under the brand names 'Buckle' and 'The Buckle'. Buckle markets a wide selection of mostly brand-name casual apparel including denim, other casual bottoms, tops, sportswear, outerwear, accessories, and footwear.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.